Arrhythmia Section, Hospital Clínic, Cardiovascular Clinic Institute, University of Barcelona, Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
J Cardiovasc Electrophysiol. 2020 Apr;31(4):868-874. doi: 10.1111/jce.14360. Epub 2020 Jan 29.
Micra transcatheter pacemaker system (TPS) usually achieves low implant pacing threshold (IPT). However, IPT may increase in some patients during follow-up.
To apply implant parameters in predicting long-term occurrence of very high pacing threshold (VHPT) in patients with Micra-TPS.
A cohort of 110 consecutive patients implanted with a Micra-TPS from 2014 to 2018 was evaluated at discharge and at 1, 12, 24, 36, and 48 months follow-up. VHPT was defined as greater than 2 V/0.24 ms. VHPT predictors were identified.
Micra-TPS was implanted successfully in 108 patients (98.2%). During a mean follow-up of 24 ± 16 months, 18 patients (16.7%) died of causes nonpacemaker-related, and 4 (3.8%) developed VHPT. Patients with VHPT had higher IPT and lower implant impedance than patients with non-VHPT: 1 ± 0.31 vs 0.55 ± 0.29 V/0.24 ms (P = .003) and 580 ± 59 vs 837 ± 232 Ω (P = .03), respectively. IPT and impedance had excellent discriminative power to predict VHPT (area under the curve: 0.85 ± 0.07 and 0.91 ± 0.05, respectively). Negative predictive value (NPV) of IPT ≤ 0.5 V/0.24 ms was 100%; positive predictive value (PPV) was 8% throughout follow-up. Implant impedance ≤ 600 Ω had NPV of 99% throughout follow-up, whereas PPV varied: 16%, 21%, 16%, and 28% at 1, 12, 24, and 36 months, respectively. Sequential combination of IPT greater than 0.5 V/0.24 ms and impedance ≤ 600 Ω improved PPV to 25%, 35%, 27%, and 44%, respectively, whereas NPV remained 99% throughout follow-up.
Despite favorable long-term electrical performance of Micra-TPS, a small percent of patients developed VHPT during follow-up. A sequential combination of IPT and impedance could allow the implanter to identify patients who will develop VHPT during long-term follow-up.
Micra 经导管心脏起搏器系统(TPS)通常可实现较低的植入起搏阈值(IPT)。然而,在随访过程中,某些患者的 IPT 可能会升高。
探讨植入参数对 Micra-TPS 患者长期出现极高起搏阈值(VHPT)的预测价值。
回顾性分析 2014 年至 2018 年期间连续 110 例植入 Micra-TPS 的患者资料。在出院时及 1、12、24、36 和 48 个月时随访时评估患者。VHPT 定义为大于 2 V/0.24 ms。分析预测 VHPT 的相关因素。
108 例患者(98.2%)成功植入 Micra-TPS。平均随访 24±16 个月期间,18 例(16.7%)患者因非起搏器相关原因死亡,4 例(3.8%)发生 VHPT。与非 VHPT 患者相比,VHPT 患者的 IPT 更高,植入阻抗更低:1±0.31 V/0.24 ms 比 0.55±0.29 V/0.24 ms(P=0.003)和 580±59 Ω 比 837±232 Ω(P=0.03)。IPT 和阻抗对预测 VHPT 具有良好的区分能力(曲线下面积:0.85±0.07 和 0.91±0.05)。IPT≤0.5 V/0.24 ms 的阴性预测值(NPV)为 100%;整个随访期间的阳性预测值(PPV)为 8%。植入阻抗≤600 Ω 的 NPV 为 100%,而整个随访期间的 PPV 分别为 16%、21%、16%和 28%。IPT 大于 0.5 V/0.24 ms 与阻抗≤600 Ω 的连续组合可使 PPV 分别提高至 25%、35%、27%和 44%,而 NPV 仍为 100%。
尽管 Micra-TPS 具有良好的长期电性能,但在随访期间仍有一小部分患者发生 VHPT。IPT 和阻抗的连续组合可帮助植入医生识别出在长期随访中会发生 VHPT 的患者。